Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
The United Laboratories International Holdings Ltd (United Lab) is a pharmaceutical company that manufactures and sells pharmaceutical products. The company offers products through divisions such as preparation products, intermediate products, capsule products, raw material products and health products. It also provides antibiotics, pharmaceutical raw materials and intermediates, material products and healthcare products. United Laboratories' drug products include amoxicillin capsules, ampicillin capsules, clavulana capsules, levofloxacin hydrochlorid, and cefuroxime axetil tablets, among others. It sells its products through a network of distributors in Europe, North America, East Africa, and Southeast Asia. United Lab is headquartered in Yuen Long, Hong Kong.
Headquarters
Hong Kong
Address
6 Fuk Wang Street, Yuen Long Industrial Estate, Hong Kong City
Website
www.tul.com.cn
Telephone
852 26871033
No of Employees
17,000
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
3933 (HKG)
Revenue (2024)
$1.9B
0.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-1.5%
(2024 vs 2023)
Market Cap*
$2.2B
Net Profit Margin (2024)
XYZ
-1.7%
(2024 vs 2023)
* As of and is in US$
The United Laboratories International Holdings Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Antimicrobial for Injection | Diabetes Care Services | TUL |
| Anti-cold, Cough Medicine | USLEN | |
| Ophthalmic Drugs | ||
| XYZ | ||
| XYZ | ||
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In March, the company entered into an agreement with Novo Nordisk for UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases. |
| 2022 | Financing Agreements | In December, the company entered into the Facility Letter with Hang Seng Bank Limited for a term loan facility of HKD200,000,000. |
| 2022 | Financing Agreements | In December, the company entered into the Facility Letter with Bank of Communications (Hong Kong) Limited for a term loan facility of HK$300,000,000. |
Competitor Comparison
| Key Parameters | The United Laboratories International Holdings Ltd | Tasly Pharmaceutical Group Co Ltd | Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd | Sinovac Biotech Ltd | Jinyao Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Hong Kong | China | China | China | China |
| City | Hong Kong City | Tianjin | Tianjin | Beijing | Tianjin |
| State/Province | - | Tianjin | Tianjin | Beijing | Tianjin |
| No. of Employees | 17,000 | 10,958 | 3,835 | 3,037 | 2,884 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Tsoi Hoi Shan | Chairman | Executive Board | - | 47 |
| Leung Wing Hon | Secretary; Chief Financial Officer; Vice Chairman | Executive Board | - | 62 |
| Zhu Su Yan | Director; Vice President | Executive Board | - | 60 |
| Zou Xian Hong | Vice President; Director | Executive Board | - | 60 |
| Fang Yu Ping | Director; Vice President | Executive Board | - | 62 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer